Literature DB >> 15364163

Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population.

Yoshiharu Tokuyama1, Kana Matsui, Toru Egashira, Osamu Nozaki, Toshiharu Ishizuka, Azuma Kanatsuka.   

Abstract

To address the possibility that the partial disruption of Glucagon-like peptide-1 (GLP-1) signaling could cause diabetes, we tried to detect the mutation in GLP-1 receptor (GLP-1R) gene in the population with type 2 diabetes. Genomic DNA was extracted from 36 unrelated Japanese type 2 diabetic subjects and directly sequenced for the GLP-1R gene. For the detected polymorphisms, 791 patients with type 2 diabetes and 318 controls were screened by polymerase chain reaction-restricted fragment length polymorphism and association study was carried out. Five missense and four silent variants were detected in the GLP-1R gene. There were no significant differences in the frequencies of Pro7Leu, Arg44His and Leu260Pro polymorphism between the diabetic and control groups. And also there were no significant differences in body mass index (BMI), onset age and fasting IRI among the wild type, heterozygote and homozygote of these variants in diabetic patients. Thr149Met mutation was detected in one case among 791 type 2 diabetes patients, but not in control subjects. The patient with this mutation exhibited impairment of both insulin secretion, insulin sensitivity and glucose effectiveness, which may be partially explained by Thr149Met mutation in GLP-1R, though family linkage analysis and function analysis remain to be examined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364163     DOI: 10.1016/j.diabres.2004.02.004

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  23 in total

1.  Relation of the rs6923761 gene variant in glucagon-like peptide 1 receptor with weight, cardiovascular risk factor, and serum adipokine levels in obese female subjects.

Authors:  Daniel Antonio de Luis; Rocío Aller; B de la Fuente; D Primo; Rosa Conde; Olatz Izaola; Manuel Gonzalez Sagrado
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Authors:  Laurence J Miller; Quan Chen; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Maoqing Dong
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

4.  Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.

Authors:  Quan Chen; Delia I Pinon; Laurence J Miller; Maoqing Dong
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

Review 5.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

6.  Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Celine Valant; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  Mol Pharmacol       Date:  2011-05-26       Impact factor: 4.436

Review 7.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

8.  Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

Authors:  K Coopman; R Wallis; G Robb; A J H Brown; G F Wilkinson; D Timms; G B Willars
Journal:  Mol Endocrinol       Date:  2011-08-25

9.  Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go ...

Authors:  Michael A Nauck; Irfan Vardarli
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

10.  Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor.

Authors:  Daniel Antonio de Luis; Rocío Aller; Olatz Izaola; R Bachiller; D Pacheco
Journal:  J Endocrinol Invest       Date:  2014-06-27       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.